Biogen Idec, Eisai sign multi-drug deal in the area of Alzheimer's disease
To further enhance its strong neurodegenerative disease pipeline, Biogen Idec Inc. will co-develop and co-commercialize two of Eisai Co. Ltd.'s Alzheimer’s disease candidates--the Phase II-ready ß-site amyloid precursor protein cleaving enzyme (BACE) inhibitor E2609 and Phase II BAN2401, an anti-amyloid beta (Aß) antibody. In addition, Eisai has the option to jointly develop and commercialize two of Biogen’s AD candidates--the Phase Ib Aß antibody BIIB037 and preclinical BIIB076, an anti-tau monoclonal antibody.
- Large Molecule
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com